GlassScriptPhysician profile
Kent A Bogner
NPI 1295720340
$9,998.36
in general payments reported to CMS, 2019-2025
55 companies · $1,629 in 2025
The $1,629 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,003 · 2020: $571 · 2021: $1,785 · 2022: $1,346 · 2023: $1,824 · 2024: $1,841 · 2025: $1,629.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,250 · Education: $43.98.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,249.64 |
| Education | $43.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,680.10 | 2020-2025 | Vraylar, Ubrelvy, Qulipta |
| Pfizer INC. | $740.21 | 2020-2025 | |
| Novo Nordisk INC | $729.31 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $699.41 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Astrazeneca Pharmaceuticals LP | $657.95 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Abbott Laboratories | $612.98 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2, Proclaim |
| Lilly USA, LLC | $557.41 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Amgen INC. | $482.60 | 2019-2025 | Repatha, Otezla, Evenity |
| Glaxosmithkline, LLC. | $332.78 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $326.62 | 2019-2025 | Xifaxan |
| Otsuka America Pharmaceutical, INC. | $283.69 | 2019-2025 | Rexulti |
| Biohaven Pharmaceuticals, INC. | $222.96 | 2020-2021 | |
| Astellas Pharma US INC | $197.77 | 2019-2025 | Veozah, Myrbetriq |
| Janssen Pharmaceuticals, INC | $193.31 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $178.24 | 2020-2023 | Belsomra, Steglatro, Lagevrio |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kent Bogner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.